Form 4: AbbVie EVP Scott T. Reents Reports Stock and Option Awards Vesting
SEC Form 4 Filing
EVP and CFO of AbbVie, Scott T. Reents, reports the vesting of performance-based stock awards and a new stock option grant.
Summary
- Scott T. Reents, EVP and CFO of AbbVie, filed a Form 4 detailing changes in his beneficial ownership of AbbVie stock.
- On February 13, 2025, performance-based stock awards granted in 2022, 2023 and 2024 vested, resulting in the acquisition of 5,845, 2,398, 8,912 and 7,608 shares of AbbVie common stock, respectively.
- These shares will be issued to Reents on February 28, 2025.
- Reents also acquired 27,343 options to buy AbbVie common stock at an exercise price of $192.86 on February 13, 2025.
- The options become exercisable in annual increments starting February 13, 2026.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The vesting of performance-based awards suggests the company is meeting its goals, and the granting of stock options aligns executive interests with shareholders.
Positives
- The vesting of performance-based awards suggests that AbbVie has met certain performance goals related to earnings per share and relative total shareholder return, as well as relative return on equity.
- The grant of stock options aligns Reents' interests with those of shareholders, incentivizing him to drive long-term value creation.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with shareholders. The vesting of performance-based awards suggests that AbbVie is achieving its performance targets.
Comparison to Industry Standards
- Executive compensation packages, including stock options and performance-based awards, are common practice among large pharmaceutical companies like AbbVie.
- Companies such as Johnson & Johnson, Pfizer, and Merck also utilize similar compensation structures to incentivize their executives.
- The specific terms of these awards, such as vesting schedules and performance metrics, can vary widely based on company-specific goals and industry benchmarks.
Stakeholder Impact
- The vesting of performance-based awards and granting of stock options can positively impact shareholders by aligning management's interests with the company's performance.
- Employees may view this as a positive sign of the company's success and commitment to its executives.
Next Steps
- The shares from the vested awards will be issued to Reents on February 28, 2025.
- Reents will be able to exercise his stock options starting February 13, 2026, in annual increments.
Key Dates
| Date | Description |
|---|---|
| 02/17/2022 | Date of grant for performance share award and performance-vesting restricted stock unit award. |
| 02/16/2023 | Date of grant for performance-vesting restricted stock unit award. |
| 02/15/2024 | Date of grant for performance-vesting restricted stock unit award and employee stock option. |
| 02/13/2025 | Date of transaction and vesting of performance-based stock awards and grant of stock options. |
| 02/28/2025 | Date shares will be issued to the reporting person. |
| 02/13/2026 | First date options become exercisable in annual increments. |
| 02/13/2027 | Second date options become exercisable in annual increments. |
| 02/13/2028 | Third date options become exercisable in annual increments. |
| 02/12/2035 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.